Compare GSK plc (GSK) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Revvity Inc — how do they compare? GSK plc trades at $52.64 (market cap $101.34B), while Revvity Inc trades at $111.06 (market cap $12.42B). The key difference: GSK plc is far larger — about 8.2× Revvity Inc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | RVTY | |
|---|---|---|
Market Cap | $101.34B | $12.42B |
Sector | Health | Technology |
52-Week High | $61.18 | $117.75 |
52-Week Low | $36.20 | $82.26 |
Enterprise Value | $121.95B | $14.91B |
Dividend Yield | 3.49% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
RVTY trades at $110.99, down slightly by 0.2% today, near the analyst consensus price target of $111.43. The stock shows a bullish technical trend with recent earnings beats in Q3 2025, Q4 2025, and Q1 2026. Strong profitability metrics include a gross margin of 54.32% and net income margin of 8.26%. Recent news highlights AI integration advancements and FDA clearances, supporting growth prospects.
The outlook is positive with analyst consensus leaning buy (51.72%) and no sell ratings. Key risks include margin pressure and macroeconomic headwinds affecting cash flow, which turned negative in 2025 and 2026. The upcoming Q2 2026 earnings report on August 4, 2026, will be critical for validating current growth trajectory and investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
